DURATOCIN (Ferring Pharmaceuticals Pty Ltd)
Product name
DURATOCIN
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
219 working days (255)
Active ingredients
carbetocin
Registration type
EOI
Indication
DURATOCIN is now also indicated for the treatment of the prevention of uterine atony and excessive bleeding following delivery of the infant by emergency caesarean section or vaginal delivery. Duratocin must be administered after delivery of the infant.